Fast&Up Parent Fullife Healthcare Raises Rs 300 Cr Led by Elev8

Why It Matters

The infusion of growth capital positions Fullife to capture a larger share of India’s fast‑growing health‑and‑wellness market and to scale its D2C model internationally, improving profitability prospects.

Key Takeaways

• Raised Rs 300 cr (~$36 M) Series D funding.
• Revenue up 36% YoY to Rs 256 cr (~$31 M).
• Losses halved to Rs 13.4 cr (~$1.6 M).
• Expanding into digestive, sleep, protein nutrition segments.
• Targeting UK, GCC, US markets via stronger distribution.

Pulse Analysis

India’s consumer health sector has attracted a wave of venture capital as millennials prioritize fitness and preventive care. Elev8 Venture Partners’ decision to lead Fullife’s Rs 300 crore Series D marks its inaugural investment in a direct‑to‑consumer (D2C) business, signaling confidence in the scalability of online‑first nutrition brands. The funding round, which also included Elev8’s limited partners, aligns with a broader trend of investors seeking exposure to high‑margin, subscription‑friendly product categories that can leverage data‑driven marketing. For Fullife, the partnership brings not only capital but also strategic guidance on channel optimization and brand storytelling.

Fullife’s portfolio—Fast&Up, Chicnutrix and NightOut—covers more than 100 SKUs spanning sports nutrition, women’s wellness and beauty care. In FY25 the company posted a 36.4% revenue jump to Rs 256.04 crore (≈$31 million) and narrowed its net loss to Rs 13.42 crore (≈$1.6 million), reflecting tighter cost control and higher gross margins on premium supplements. The fresh capital will be deployed to scale manufacturing capacity, introduce new formats such as ready‑to‑drink protein shakes, and accelerate product innovation in under‑penetrated categories like digestive health and sleep support. These moves aim to deepen consumer loyalty and improve lifetime value.

Beyond domestic growth, Fullife is targeting a foothold in the United Kingdom, the Gulf Cooperation Council and the United States, markets where health‑focused D2C brands have already proven successful. Strengthening distribution partnerships and boosting brand visibility abroad will require localized marketing, regulatory compliance, and supply‑chain resilience. If the company can replicate its Indian growth trajectory, it could become one of the few Indian‑origin wellness brands with a truly global footprint, challenging incumbents and attracting further institutional interest. Analysts therefore view the Series D as a catalyst for both revenue acceleration and a path toward sustainable profitability.